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Abstract
Background The role of endovascular interventions in
managing dural arteriovenous fistulas (DAVFs) is increas-
ing. Furthermore, in patients with aggressive DAVFs,
different surgical interventions are required for complete
obliteration or disconnection. Our objective was to evaluate
the management of patients with intracranial DAVFs treated
in our institution to identify the parameters that may help
guide the long-term management of these lesions.
Methods The hospital records of 53 patients with intracra-
nial DAVFs were reviewed. We then conducted a system-
atic telephone interview to obtain long-term follow-up
information.
Results The main presenting symptoms were tinnitus and
headache. Nineteen (35%) patients presented with intracra-
nial bleeding, 84% of patients scored between 0 and 2 using
a modified Rankin Scale at the last follow-up visit. Twenty-
four patients were treated surgically. Overall postoperative
complications occurred in seven (29%) surgically treated
patients, but only two patients permanently worsened. For
patients with Borden type II and III fistulas, the annual
incidence of hemorrhage was 30%. Two patients had late
recurrences of surgically and endovascularly occluded
DAVFs. Long-term follow-up showed that compared with
spinal DAVFs, only 50% of intracranial DAVFs showed
complete remission of symptoms, 41% partial remission,
6% no remission and 4% deterioration of symptoms that led
to treatment of the DAVF.
Conclusion In general, intracranial DAVFs can be success-
fully surgically managed by simple venous disconnection in
many cases. However, half of the patients do not show
complete remission of symptoms. Age and the occurrence
of perioperative complication were the most important
determinants of outcome.
Keywords Dural arteriovenous fistula . Endovascular
treatment . Surgical treatment results . Intracranial
hemorrhage
Introduction
Dural arteriovenous malformations, also called dural arte-
riovenous fistulas (DAVFs), are complex acquired vascular
lesions. The classification systems that are widely accepted
use venous drainage pattern to categorize DAVFs [3, 7].
DAVFs with retrograde leptomeningeal venous drainage or
an associated venous varix are defined as high-risk fistulas
and are associated with a grave natural history. Cortical
venous reflux, either untreated or persistent after incom-
plete treatment, was reported to cause an annual mortality
rate of 10.4% and an annual morbidity rate of 15% [36].
Hemorrhage or progressive neurological deficits com-
pose the typical presentation of high-risk fistulae [17].
Rarely are they clinically quiescent. Cranial DAVFs without
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cortical venous drainage are considered to be benign, with a
clinical presentation characterized by the absence of
aggressive clinical events [30].
Prompt diagnosis and treatment of the aggressive lesions
is mandatory. Primarily taking venous drainage into
consideration, a careful evaluation is needed for the choice
of treatment. Many DAVFs can be successfully managed
with endovascular techniques [26]. However, a consider-
able number of patients require different forms of surgical
treatment because they have DAVFs with anatomic
features that are not suitable for endovascular treatment
[17].
Studies reporting long-term results of treatment—either
surgical or endovascular—are scarce. Here we systemati-
cally reviewed our experience with 53 patients with cranial
DAVFs that were evaluated and treated at our institution.
We were interested specifically (1) in the rate of events after
diagnosis and before treatment, (2) after incomplete
treatment, (3) after complete DAVF occlusion, and (4) the
recurrence rate.
Materials and methods
First, we retrospectively reviewed the charts of our patients
with intracranial DAVFs between 1999 and 2007. Patient
records, cerebral angiograms, operative reports, and clinical
notes were analyzed. We then conducted a systematic
telephone interview to obtain long-term follow-up and to
assess the modified Rankin Score (mRS) of the patient [21].
If the patient could not be reached via telephone or was not
able to respond adequately, a close relative was contacted to
provide the required information.
Management
All intracranial DAVFs were evaluated by an interdisci-
plinary team of neurosurgeons, neuroradiologists and
neurologists. The assessment of patients included a detailed
medical history, a full neurological examination, and at
least one angiogram. In the angiogram the following
features were evaluated: location of fistula, venous drainage
and presence of retrograde leptomeningeal venous drainage.
On the basis of proximity of involvement of the venous
sinus, DAVFs were classified into the following locations:
cavernous, transverse-sigmoid, superior sagittal sinus,
ethmoidal, tentorial and jugular foramen DAVFs. We used
the more neurosurgical oriented Borden classification of
cranial DAVFs [3, 7].
Our team determined whether patients were candidates
for potential endovascular cure or for preoperative embo-
lization. If a Borden II or III fistula was not amenable to
endovascular management (i.e., due to inaccessibility or
diffuse arborization) or not cured by embolization, the
patient underwent surgical treatment.
Intraoperatively, we used digital subtraction angiography
(DSA) in selected cases to verify obliteration of the fistula.
Intraoperative indocyanine green angiography (ICGA) was
used after the advent of this technique in 2003 in our
hospital. Postoperative imaging consisted of routine post-
operative DSA performed between days 1–7. We repeated
the angiogram if the patient presented with new symptoms
after a primary uneventful course. Routine follow-up
angiography was not performed if a postoperative angio-
gram showed complete occlusion of the fistula.
Statistical analysis
Univariate associations were assessed by Pearson’s χ2 test
with continuity correction. Significance level was set at a p
value of less than 0.05. All statistical analyses were
performed using the software program SPSS (SPSS,
Chicago, IL, USA).
Results
Between 1999 and 2007 we treated 53 patients (male/
female ratio 1:1.08) at our institution (Fig. 1). The mean
age at presentation was 57 years (range 25–61).
Location
DAVFs were situated in the transverse sigmoid sinus in 30
patients, in the superior sagittal sinus in 11, and in the
cavernous sinus in eight patients. Three patients had
posterior fossa fistulas and one had an ethmoidal DAVF.
All of the fistulas to the superior sagittal sinus, posterior
fossa, and anterior cerebral fossa were Borden type III.
Twelve Borden type II fistulas were found in the transverse-
sigmoid sinus and five in the cavernous sinus (Borden type
I fistulas were distributed between the transverse-sigmoid
sinus (n=10) and the cavernous sinus (n=3).
Presentation
The main presenting symptoms were tinnitus and headache
(Table 1).
Nineteen patients suffered intracranial bleeding (14
intraparenchymal, two both intraparenchymal and sub-
arachnoid and three subarachnoid). The hemorrhage led
mostly to presentation with headache (n=9). Other pre-
sentations included motor deficit (n=5), seizures (n=2),
ataxia (n=2) and aphasia (n=1).
Three of the 19 (16%) fistulas that bled were Borden
type II, the remaining 16 (87%) Borden type III. In total,
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17% of all type II fistulas presented with bleeding
compared with 59% of all type III fistulas.
In eight patients with hemorrhage, the fistula was located
in the superior sagittal sinus, in seven patients in the
transverse-sigmoid sinus, in three patients in the posterior
fossa and in one patient in the anterior cerebral fossa.
Cavernous sinus fistulas were mostly found in women
(89%). Excluding cavernous sinus fistulas—which never
presented with hemorrhage—men showed a slight disposi-
tion to present with an intracranial hemorrhage, which was
not significant (64% men vs 26% women, p>0.05). Age
was not a risk factor for hemorrhagic presentation.
Treatment
Excluding the cavernous sinus fistulas where surgical
treatment was not an option, we treated 24 of the
patients surgically. Three patients had attempted endo-
vascular embolization of their fistulas before their
surgical treatment. All of them were Borden type II or
III fistulas. Of these, 14 patients were in a clinically poor
condition (Rankin grade >2).
Fifteen patients were treated endovascular (Borden type
I, n=6; type II n=2, type III n=7). Six patients were
managed conservatively, all of them had Borden type I
fistulas.
Of the 24 surgically treated patients, we selectively
disconnected the fistula in the majority of patients (n=17),
occluded the transverse-sigmoid sinus in five patients and
both occluded and disconnected the superior sagittal sinus
in two patients.
Complications after surgical treatment
Overall postoperative complications occurred in seven
(29%) surgically treated patients. One patient developed
generalized cerebral swelling, two patients had a general-
ized seizure, one patient developed hydrocephalus, one a
cerebrospinal fluid fistula, one had an epidural hematoma
and one a pulmonary embolic event. Complications were
independent of the type of fistula. In the majority of cases
(four out of seven) patients recovered to a good outcome
(mRS 0–2). Three out of seven patients with a complication
had a poor outcome (mRS 3–5) but only two of the three
patients worsened postoperatively. One of them had
generalized cerebral swelling and the other developed a
seizure disorder. The other one was in a poor condition
attributable to his intracerebral bleeding. None of the
postoperative complications were associated with an in-
complete occlusion of the fistula. Therefore, the rate of
poor outcome caused by the surgical procedure was 8%
(two out of 24 patients).
One primarily endovascular treated patient had to be
treated surgically because he suffered from cerebral
swelling caused by his hematoma. He worsened to
mRS 5. In addition, another endovascular treated patient
Fig. 1 Overview of patients
included in study according to
treatment type
Table 1 Overview of common signs and symptoms at clinical
presentation
Signs and symptoms Number of patients (n) percentage (%)
Tinnitus 13 (24%)
Headache 11 (20%)
Orbital phenomenaa 10 (19%)
Paresis 5 (9%)
Aphasia 3 (5%)
Ataxia 3 (5%)
Paresthesias 3 (5%)
Seizure 3 (5%)
Incidental 2 (4%)
All study patients (endovascular and surgically treated) are included in
the table
a The orbital phenomena occurred with approximately equal frequency of
retroorbital pulsating headache, double vision, conjunctival injection and
visual blurring
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suffered an infarction of the posterior circulation during
coil embolization of his cavernous sinus fistula. He
recovered to mRS 2.
Long-term outcome
Mean follow-up time was 35 months (range 2–
192 months). Seven (13%) patients were lost to follow
up (four in the surgical subgroup). Figure 2 shows the
outcome by mRS.
Compared with the large series of spinal DAVFs in
the literature [29], our cohort of intracranial DAVFs
showed that a significant number of patients (25) still
suffered from residual symptoms. These included tinnitus
(7), paresis (3), double vision (3) balance difficulties (5),
headache (3), visual field deficits (2), tiredness (3),
sensational deficits (1), aphasia (2) and seizures (1). Two
patients with tinnitus had a residual Borden type I fistula,
the other patients with residual symptoms had completely
obliterated fistulas.
Overall, 50% showed complete remission of symptoms,
41% partial remission, 5.5% no remission and 3.7%
showed a deterioration of symptoms that led to treatment
of the DAVF.
Rate of events after diagnosis until treatment
During the “radiological follow-up time” [32]—the time from
diagnosis of a hemorrhagic fistula until definitive treatment—
two patients, who initially presented with bleeding, had
rebleeding. The annual incidence of rebleeding in the Borden
type II-III fistulas in the hemorrhagic subgroup was 23% (two
patients in 8.48 patient years). Another patient who presented
with a nonhemorrhagic neurological deficit (NHND) suffered
a hemorrhage 395 days after diagnosis of a Borden type II
fistula in the superior sagittal sinus that was left untreated after
the patient refused surgical therapy. We calculated an overall
annual incidence of 30% (three hemorrhagic events in 9.69
patient years). None of the patients with a Borden type II or
III fistula who presented with pulsatile tinnitus or whose
fistula was discovered incidentally had a bleeding event or
developed a new NHND during the follow-up period.
Incomplete treatment of DAVFs
There were three patients that were left with incomplete
occlusion of the DAVF.
One patient presented initially 2006 with aphasia and
paresthesias evoked by a venous infarction. The angiogram
Fig. 2 Cumulative long-term
outcome by mRS of the
patients compared with their
pre-operative or pre-
interventional status. The
number of patients is shown
on the y-axis. Seven patients
were lost to follow up and
are not included in the
pre-operational/interventional
analysis
1276 Acta Neurochir (2011) 153:1273–1281
showed a Borden type III fistula to the superior sagittal
sinus and a thrombosis of the superior sagittal sinus. We
planned to selectively disconnect the fistula. The postoper-
ative angiogram showed a low-flow, small, residual fistula
that it was decided to keep under observation. Twelve months
later she complained of a new onset of memory disturbances,
which led to a new angiography that showed a recurrent
Borden type III fistula.
She refused treatment but agreed to get another close
follow-up angiogram in 3 months. She was mRS 0 at the
time of the telephone interview.
Two patients presented with tinnitus due to a Borden
type II fistula to the transverse-sigmoid sinus. We embol-
ized the fistula and the postinterventional angiogram
showed a residual Borden type I fistula. The symptoms of
the patients could be reduced with regards to their intensity.
A postinterventional angiogram after 12 months showed a
stable Borden type I fistula. The patients were in a good
condition (mRS 1) with a reduced bruit at the time of the
telephone interview.
Late recurrence or bleeding of occluded DAVFs
None of the completely occluded fistulas that we managed
had a rebleeding event.
Two patients had late recurrences with non-hemorrhagic
symptoms where each had both surgically and endovascu-
larly occluded DAVF. One patient presented initially with
consecutive bleeding episodes that led to generalized
seizures. Her fistula was Borden type III, had bilateral
feeders from the occipital arteries, the tentorial arteries and
was located at the transverse/sigmoid sinus junction
(Fig. 3). We planned to disconnect the fistula and to
occlude the trapped transverse-sigmoid sinus transition
zone, but the postoperative angiogram showed incomplete
disconnection with still residual filling of leptomeningeal
veins. We took her back to the operating room and now
also disconnected the sinus from the tentorium. The
postoperative angiogram 7 days after the second operation
showed complete disconnection in terms of retrograde
venous drainage but still some residual filling of the distal
transverse and sigmoid sinus (Fig. 4). She presented
7 months later with a new onset of seizures that initially
led to her diagnosis, without evidence of rebleeding. She
underwent angiography, showing a reperfusion of the
fistula through bilateral feeding arteries from the occipital
arteries und the ipisilateral tentorial and posterior meningeal
arteries (Fig. 5). Her fistula was occluded during another
surgical procedure by opening and occluding the lumen of
the lateral transverse and upper sigmoid sinus with
Gelfoam, paying attention not to miss a parallel venous
channel [5] (Fig. 6). She developed meningitis in the late
postoperative period and recovered from preoperative mRS
4 to mRS 3.
Another patient presented 12 years after initial emboli-
zation of a transverse-sinus fistula at an outside hospital
with recurrence of tinnitus. Her angiogram showed a
Borden type III fistula to the superior sagittal sinus. She
was successfully treated with preoperative embolization and
surgical disconnection of the fistula. Unfortunately, detailed
past medical records were no longer available.
Discussion
Presentation of DAVFs
Mean age at presentation was 57 years, which is very well
in accordance with reports from other groups [10, 36].
Considering presentation, a variety of signs and symptoms
Fig. 3a–c DSA images of a patient with post-thrombotic dural AV
fistula to the left transverse sinus. a Injection of the left ECA shows
multiple arterial feeders, mainly from the occipital artery (black
arrows) to a “trapped“ segment of the transverse sinus (white arrow).
b Venous outflow via multiple cortical veins (white arrows) and into
the deep venous system which shows multiple small venous vessels
(black arrow). c Injection of the left ICA demonstrating occlusion of
the proximal left transverse sinus
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is reported in the literature that occur in very different
proportions, although some percentages seem to be stable.
Thirty-eight percent of our patients presented with a
hemorrhage, which is higher than reported numbers of
22% [31], 18% [18] and 16% [11]. Most of the hemor-
rhagic events were intracerebral as opposed to subarach-
noid. Our relation of about 3:1 (intracranial bleeding to
subarachnoid bleeding) can also be found elsewhere [10].
Twenty-eight percent of these patients were over 65 years
(mean age of the hemorrhagic group was 60) at the time of
diagnosis. Another series of DAVFs with a higher percent-
age of older patients also had a higher hemorrhagic
proportion [37]. A higher frequency of angiographic
diagnostics in the older age group could have led to this
higher number, but the exact reason will remain elusive.
Our seizure frequency of 5% is in line with published
data [31, 36]. Likewise, a significant proportion of DAVFs
in this series drained to the transverse/sigmoid sinus [7].
The role of venous outflow obstruction and the revascular-
ization of primitive fistulous tracts or even neoangiogenesis
due to venous hypertension in the pathophysiology of
DAVFs is widely accepted now and experimentally proven
[14, 35]. The winding course of venous outflow in the
transverse and sigmoid sinus may contribute to minimal
local venous hypertension with the development of fistu-
lous tracts over the long term. Of note is the higher
percentage of patients harboring fistulas draining to the
superior sagittal sinus (20%) in our series compared with a
percentage of 5-10% that is reported in the literature [4, 31].
Risk factors for hemorrhagic events have been explored
extensively in the past, with the single most important
factor being retrograde leptomeningeal drainage. A recently
published series of a significant number of patients added
older age, male sex and location in the posterior fossa as
risk factors [31]. We also had a higher percentage of male
patients that suffered a hemorrhagic event, although this
was not significant. We could not find any correlation with
age and location. The gender-specific risk is also known
from arteriovenous malformations [23] and ICH.
Indications for treatment
Concerning bleeding risk of Borden type II and III fistulas,
a prospective study by van Dijk et al. [36] reported 8.1%
per year, which was also found in a retrospective Swedish
study, reporting 7.8 % per year [32]. In the light of a recent
paper by Strom et al. [34], one must further differentiate
between the bleeding risk of asymptomatic fistulas and
symptomatic fistulas in close analogy to cerebral aneur-
ysms. Asymptomatic fistulas had an annual event rate of
Fig. 4 a External carotid angio-
gram after surgical packing of
the trapped sinus segment. Note
persistent filling of a venous
channel in the region of the left
transverse sinus draining into
small caliber cortical veins
(arrow). b After the second
surgery there is only subtle
filling of the venous pouch
(arrow) and no connection to
cortical veins
Fig. 5 a Common carotid injec-
tion after 6 months shows
recurrence of dural AV-fistula
with new feeders from the left
occipital artery (black arrow)
and b cortical venous drainage
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1.4% versus 19.0% of symptomatic fistulas. Using the
recently published approach of measuring bleeding risk with
time at risk after diagnosis of the fistula [32], our overall
bleeding risk would be an estimated 30% per year. This
number may not represent the actual bleeding risk. None of
our patients with a type II or III fistula presenting with
tinnitus or incidentally had a bleeding event or experienced
the development of a new NHND, which according to Strom
et al. [32] shifts increases our overall estimate of bleeding
risk due to bias. Furthermore, this demonstrates the
limitations of the method when a short interval between
diagnosis and treatment is used for calculation and therefore
not enough time at risk can be assembled.
On the other hand, Duffau et al. [12] experienced a 35%
rebleeding rate in the first days (mean: 20) after the first
hemorrhagic event. Contrary to this, we did not see any
rebleeding event of the hemorrhagic fistulas in the first
days after the diagnosis was established. It should be
emphasized that the rate of bleeding as the presenting
symptom is considerably higher in patients with Borden
III compared with Borden II fistulas, i.e., that the direct
leptomeningeal retrograde drainage translates into a
higher risk of hemorrhage.
Relief of symptoms
Our mean follow-up period of 32 months lies well between
previously reported 12 months [17] and 6.6 years [4]. We
generally had a satisfactory outcome, with more than 85%
of our patients showing mRS 0–2, Kakarla et al. [17]
reported about 95% of their patients having GOS 4–5.
Considering that over 50% of our patients were mRS 3–5
preoperative/interventional, the reduction to 15% of
patients being mRS 3–5 in the long term is a satisfactory
outcome.
Overall, 50% showed complete remission of symptoms,
41% partial remission, 5.5% no remission and 3.7%
showed a deterioration of symptoms that led to treatment
of the DAVF.
Similar results were obtained in previous studies [27].
This is comparable to spinal DAVFs [25] and probably due
to the irreversible initial neuronal damage and—in the case
of tinnitus—due to mechanisms still unknown to cause the
symptoms primarily.
Therapeutic options
When treating a patient with a cranial DAVF, the risks of
intervention must be carefully weighed against the
lesion’s expected clinical course based on available
natural history studies. Next to a conservative approach
of wait-and-see, the therapeutic armamentarium to treat
cranial DAVFs today comprises microsurgical disconnec-
tion, endovascular embolization [9], selective sinus
obliteration, or stereotactic radiosurgery [6]. For symp-
tomatic Borden type II and III fistulas the high event-risk
mandates immediate intervention. The therapeutic delay of
stereotactic radiosurgery would be unacceptable for most
patients except those with very high peri-procedural risks.
Stereotactic radiosurgery may be a reasonable alternative
in asymptomatic patients and those that carry a high peri-
procedural risk, but this has to be proven by further
studies [38].
Due to technological advances, an increasing number of
fistulas can and will be treated endovascularly, with
excellent results in experienced hands [9, 13, 33]. Still,
even in these studies, a significant number of patients will
need additional surgical treatment.
Complication rates range from 5 to 10% [13, 33],
including permanent neurologic deficits. Outcome analysis
revealed comparable results to our series [20].
When comparing traditional surgery with modern
embolization techniques, it should be considered that
there is significant radiation exposure during long-term
embolization sessions, the danger of arterial embolization
and the fact that so far only the results of the most
experienced centers have been published.
Fistulas of the cavernous sinus should be reserved for
endovascular management. Surgery on these lesions carries
a high risk and the endovascular management has proven to
have a generally good outcome [1, 2].
For all other locations interdisciplinary management
and case-based decisions on the individual level should
govern treatment. Excellent results with surgical [17] or
endovascular [22] approaches have been reported. Com-
plexity and location of the lesion and single-center
experience should determine the physician’s preferences
of recommendations for treatment to the patient. Simple
surgical disconnection is sufficient in the majority of
surgical cases.
Fig. 6 Left common carotid injection after third surgery shows
complete occlusion of the fistula
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Incomplete treatment
The goal of treatment of high-risk DAVFs must always be
directed to reduction of bleeding risk and symptom relief.
Apart from the landmark paper by van Dijk et al. [36], few
long-term observations have been published prospectively
on DAVFs with persistent cortical reflux.
Whereas downgrading of DAVFs from high risk to low
risk is a well accepted treatment since Mironov’s first
description [24], worsening of the type of venous drainage
has also been reported after incomplete treatment potential-
ly causing catastrophic events [8]. Due to the fact that
persistent cortical reflux is the major contributing factor to
increased bleeding risk, incomplete treatment should be
corrected by a subsequent second procedure. Spontaneous
resolution of higher grade DAVFs within 2–10 months has
been reported, although the sizes of DAVFs were not
specified [28, 30].
Late recurrence
We saw two patients who had a late recurrence of their
primarily endovascular (one case) and surgically (one
case) treated fistula. According to one hypothesis,
primordial arterio-venous channels that persist after
embryologic closure that are reperfused due to a shift
in pressure gradients after an increase in venous
intravascular pressure [16, 35]. The fistula that was
treated surgically was disconnected and the transverse
and sigmoid sinus trapped. The postoperative angiogram
showed complete disconnection but residual filling of the
trapped sinus. This may have indicated that flow dynamics
were not completely changed and may have facilitated
opening of new fistula channels. The phenomenon of
reperfusion is only scarcely reported in the literature [15,
19, 28].
Reducing complications in surgery
Although our peri-operative complication rate of 29% is
well in line with previously reported rates of 32% [17],
it has to be emphasized, however, that the rate of clinically
significant complications was less than 10% (two out of
24 patients deteriorated to a Rankin grade >2 after
surgery). Careful close pre- and postoperative monitoring
and a judicious allocation to the different treatment
modalities are mandatory for these patients. Redirecting
cerebral blood flow often carries an inherent risk of
experiencing unexpected complications unrelated to treat-
ment modalities. Very low surgical complication rates with
complications having no influence on postoperative
outcome have also been reported, but should be inter-
preted cautiously [10].
Conclusion
Here we present our 8-year experience of the management of
DAVFs. The major determinants for hemorrhagic events—
leptomeningeal venous drainage and gender—were also
found in our cohort. We showed that, in general, DAVFs can
be managed, leading to a very satisfactory outcome; however,
half of the patients do not show complete remission of
symptoms. Age and the occurrence of perioperative compli-
cation were the most important determinants of outcome. The
phenomenon of reperfusion should be considered in the
follow-up of these patients.
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